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ABSTRACT
Background
Understanding the mechanisms of amyloid-b protein (Ab) production and clearance in the
brain has been essential to elucidating the etiology of Alzheimer disease (AD). Chronically
decreasing brain Ab levels is an emerging therapeutic approach for AD, but no such disease-
modifying agents have achieved clinical validation. Certain proteases are responsible for the
catabolism of brain Ab in vivo, and some experimental evidence suggests they could be used
as therapeutic tools to reduce Ab levels in AD. The objective of this study was to determine if
enhancing the clearance of Ab in the brain by ex vivo gene delivery of an Ab-degrading
protease can reduce amyloid plaque burden.
Methods and Findings
We generated a secreted form of the Ab-degrading protease neprilysin, which significantly
lowers the levels of naturally secreted Ab in cell culture. We then used an ex vivo gene delivery
approach utilizing primary fibroblasts to introduce this soluble protease into the brains of b-
amyloid precursor protein (APP) transgenic mice with advanced plaque deposition. Brain
examination after cell implantation revealed robust clearance of plaques at the site of
engraftment (72% reduction, p¼ 0.0269), as well as significant reductions in plaque burden in
both the medial and lateral hippocampus distal to the implantation site (34% reduction, p ¼
0.0020; and 55% reduction, p ¼ 0.0081, respectively).
Conclusions
Ex vivo gene delivery of an Ab-degrading protease reduces amyloid plaque burden in
transgenic mice expressing human APP. These results support the use of Ab-degrading
proteases as a means to therapeutically lower Ab levels and encourage further exploration of
ex vivo gene delivery for the treatment of Alzheimer disease.
The Editors’ Summary of this article follows the references.
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The pathologic hallmarks of Alzheimer disease (AD) are
extracellular plaques of amyloid-b protein (Ab) and intra-
neuronal neuroﬁbrillary tangles of tau protein, both of which
accumulate in brain regions mediating memory and cogni-
tion [1]. All known early-onset, inherited forms of AD arise
from mutations in the b-amyloid precursor protein (APP),
from which the Ab peptide is generated, or the presenilins,
which are the proteases that effect the cleavage of APP, which
liberates Ab. Both amyloid plaques and soluble Ab oligomers
are believed to have neurotoxic effects [2,3], and evidence
suggests that Ab neurotoxicity can promote neuroﬁbrillary
tangle formation [4,5]. Though approved treatments for AD
ameliorate only the symptoms, potentially disease-modifying
interventions under development focus on therapeutically
lowering Ab production [6] or enhancing Ab clearance [7,8].
The role of Ab degradation in the clearance of the Ab
peptide is becoming more broadly understood and appre-
ciated, with the proteases neprilysin [9], insulin-degrading
enzyme [10,11], endothelin-converting enzymes 1 and 2 [12],
plasmin [13], and cathepsin B [14] all capable of regulating Ab
levels in vivo. Supporting a therapeutic function for Ab-
degrading proteases, both transgenic overexpression [15] and
direct viral vector injection [14,16,17] of these enzymes have
been shown to potently lower Ab levels and plaque burden
and reduce Ab-associated neuropathology. The applicability
of these approaches for AD treatment in humans is uncertain,
and alternative methods of gene delivery merit exploration.
In ex vivo gene therapy, cells are taken from a patient,
genetically modiﬁed in vitro, then implanted back into the
patient to exert their new salutary effects. This approach has
produced therapeutic improvements in experimental models
of human diseases and conditions including hemophilia [18],
retinal degeneration [19], cancer [20], spinal cord injury [21],
myopathy [22], ischemia [23], Parkinson disease [24], Hun-
tington disease [25], amyotrophic lateral sclerosis [26], and
Alzheimer disease [27]. Several of these potential treatments
have advanced to human trials [28–31], with encouraging
outcomes for patients. In a recent Phase I clinical trial,
autologous ﬁbroblasts from AD patients were modiﬁed to
produce nerve growth factor and implanted into the fore-
brain, where they enhanced cholinergic function [28]. These
efforts demonstrate the feasibility of ameliorating cholinergic
cell death by providing trophic support using an ex vivo gene
delivery approach. However, because Ab-mediated synaptic
function and cytotoxicity are likely to be upstream of
neurotransmitter abnormalities in AD, enhancing Ab clear-
ance represents a more attractive target for gene therapy in
this disorder.
Neprilysin (NEP) is a type II transmembrane protein bound
to the cell membrane, where it normally degrades Ab
intracellularly and on the cell surface [32]. Cerebral NEP
levels have been reported to decrease with age and in AD
[33,34], which may contribute to disease pathogenesis by
compromising Ab catabolism. As an approach to elevate NEP
levels and improve the enzyme’s access to extracellular Ab,w e
replaced the transmembrane domain of NEP with a signal
peptide, which produced a soluble and secreted form of NEP,
termed sNEP. We then used ex vivo gene delivery utilizing
syngenic primary ﬁbroblasts to introduce sNEP into the
brains of APP transgenic mice that had advanced plaque
deposition and studied the effect of this protein on brain
amyloid pathology.
Materials and Methods
sNEP Cloning
The sNEP construct was generated by an overlapping PCR
method to fuse the 29 amino-acid signal peptide of
angiotensin-converting enzyme (ACE) to luminal residues
52–750 of neprilysin. Two PCR amplicons were generated
that consisted of the ACE signal peptide and the NEP luminal
residues, both with a complimentary 23-basepair overlap
added to the primer. In a third PCR reaction, the overlapping
amplicons were fused using the ACE signal peptide 59 and
NEP 39 primers to produce the cDNA encoding sNEP. All
constructs were cloned into the pcDNA3.1/Hygro vector
(Invitrogen, http://www.invitrogen.com/) for transient and
stable expression. The human ACE and human NEP cDNAs
have been previously described [15,35]
Cell Culture and Lentiviral Transduction
Chinese hamster ovary (CHO) and human embryonic
kidney (HEK) 293 cells were grown in Dulbecco’s modiﬁed
Eagle’s medium containing 10% fetal bovine serum, 2 mM L-
glutamine, 100 lg/ml penicillin, and 100 lg/ml streptomycin.
HEK cells stably expressing APP695 bearing the K595N/M596L
AD-causing mutation [36] and CHO cells stably transfected
with APP751 with the V717F AD-causing mutation [37] were
maintained in medium containing 200 lg/ml G418. Trans-
fections were performed with Fugene 6 (Roche, http://www.
roche.com/), and stable cell lines were selected using 400 lg/
ml hygromycin B. Cells were conditioned for Ab measure-
ments and protein analysis in Opti-MEM I (Invitrogen) for
16–18 h. For cell-free Ab degradation assays, conditioned
medium from APP-overexpressing CHO cells was combined
with 10-fold concentrated conditioned medium from CHO
cells overexpressing empty vector, NEP, or sNEP and
incubated at 37 8C for 18 h.
Lentiviral vectors were generated by inserting the sNEP
and GFP cDNAs into pCDH1 (System Biosciences, http://www.
systembio.com/) and were cotransfected with the helper
plasmids delta8.9 and VSV-G as previously described [38]
into 293-FT cells (Invitrogen). Conditioned media were
collected 50–60 h later, centrifuged at 500 g for 5 min to
remove suspended cells, and stored at  80 8C. Viral multi-
plicity of infection was estimated by cellular ﬂuorescence and
Western blotting by transducing 293-FT cells with serial
dilutions of viral supernatant. Cells were transduced for
experiments at a multiplicity of infection of six to ten viral
particles per cell with media containing 6 lg/ml polybrene.
Immunoblotting
Cells and tissue were lysed in 50 mM Tris-HCl (pH 7.4), 150
mM NaCl, 1% NP-40, protease inhibitor cocktail (Roche), 2
mM 1,10-phenanthroline, and 5 mM EDTA, and the extracts
centrifuged at 1,000 g for 10 min to remove nuclei. Protein
concentrations were determined using a bicinchoninic acid-
based assay (Pierce, http://www.perbiodirect.com/). Samples
were then subjected to SDS-PAGE and Western blotting. We
detected NEP with monoclonal antibody 56C6 (1:100 dilution;
Abcam, http://www.abcam.com/); GFP with polyclonal anti-
body A11122 (1:1,000 dilution; Invitrogen); Ab with mono-
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polyclonal antibody C9 (1:1,000 dilution) [35]. Deglycosyla-
tion was performed using PNGase F to remove N-linked
sugars (Prozyme, http://www.prozyme.com/). Western blots
were probed with anti-mouse or anti-rabbit secondary
antibodies (1:10,000 dilution) conjugated to Alexa Fluor 680
(Molecular Probes, http://probes.invitrogen.com/) or IRdye
800 (Rockland Immunochemicals, http://www.rockland-inc.
com/). Blots were detected using the Odyssey infrared
imaging system (LI-COR, http://www.licor.com/).
NEP Activity Assay
NEP proteolytic activity was measured using the substrate
3-dansyl-D-Ala-Gly-p-(nitro)-Phe-Gly (DAGNPG; Sigma,
http://www.sigmaco.com.au/) [39,40]. Cell lysate (100 lg) or
the same relative amount of concentrated conditioned
medium (prepared without protease inhibitors) was incu-
bated with 50 lM DAGNPG and 1 lM captopril (to inhibit
any ACE cleavage of DAGNPG) in a volume of 200 lla t3 78C.
Reactions were stopped by heating samples to 100 8C for 5
min, then centrifuging at 5,000 g for 5 min to remove the
denatured protein. The whole supernatant was diluted into
400 ll of 50 mM Tris (pH 7.4) and ﬂuorescence determined
using a Victor2 multilabel plate reader (excitation 342 nm;
emission 562 nm).
ELISA
ELISAs for Ab were performed as previously described
[39,41] with few modiﬁcations. 96-well ELISA plates (Costar,
http://www.corning.com/) were coated with 3.5 lg/ml of the
capture antibody. Ab was measured by capturing with
monoclonal antibody 266, speciﬁc to residues 13–28 of Ab.
Captured Ab was detected with biotinylated monoclonal
antibody 3D6, speciﬁc to residues 1–5 of the Ab N terminus
(all ELISA antibodies were gifts of Elan Pharmaceuticals,
http://www.elan.com/). ELISAs were developed by incubating
the Ab-bound biotinylated 3D6 with avidin-horseradish
peroxidase (Vector Labs, http://www.vectorlabs.com/) followed
by a 1 h incubation with QuantaBlu ﬂuorogenic peroxidase
substrate (Pierce), and the resulting ﬂuorescence (excitation
340 nm; emission 400 nm) was measured. Plate washing after
the antibody and enzyme binding steps was performed three
times for 1 min with Tris-buffered saline, 0.05% Tween 20.
Primary Fibroblast Generation and Transduction
Primary ﬁbroblasts were generated from young wild-type
littermates of J20 transgenic mice that expressed human APP.
Skin biopsies were swabbed with 70% ethanol to sterilize the
tissue, and were then minced with sterile scalpel blades in
0.25% trypsin-EDTA. Minced tissue was incubated in trypsin-
EDTA at 37 8C for 15 min and triturated to further disrupt
the tissue. Cells remaining in suspension were plated in
growth medium and allowed to expand to 90% conﬂuency.
Fibroblasts were then passaged and transduced with two
serial applications of either sNEP (treatment cells) or GFP
(control cells) lentiviral vectors to attain strong transgene
expression in all cells. Fibroblasts were passaged a maximum
of ﬁve times before injections. Conﬂuent cultures of
transduced ﬁbroblasts were maintained to observe cell
longevity and transgene expression. After 12 mo in culture,
the cells remained metabolically active and continued to
express the introduced transgene.
Mice and Surgical Procedures
The J20 line of APPSwe/Ind heterozygous transgenic mice
(C57BL/6 3 DBA2 background) [42] were aged to approx-
imately 22–23 mo before surgery to allow for substantial
plaque deposition. For surgical procedures, mice received
intraperitoneal injections of a preanesthetic mixture (a 1:1
solution of atropine sulfate and acepromazine maleate),
followed by a 2:1 solution of ketamine and xylazine. Mice
received a unilateral hippocampal injection of 500,000
ﬁbroblasts expressing sNEP or GFP to allow for comparison
to the contralateral side. The stereotaxic coordinates for graft
placement were calculated from bregma: AP 3.3 mm; L 3.3
mm; DV 3.12 mm and 1.9 mm. Cells, in a total volume of 4
ll, were injected at two dorsoventral positions to better
distribute the graft. Brains were harvested 28 d after surgery
and ﬁxed in 10% formalin for subsequent immunohisto-
chemical analysis. All animal procedures were approved by
the Harvard Standing Committee for Animal Use and by the
Animal Care and Use Committee at McLean Hospital
(Belmont, Massachusetts, United States).
Immunohistochemistry and Image Analysis
Sagittal brain sections of 18 lm thickness were deparafﬁ-
nized and hydrated through a series of graded alcohol steps
and washed in phosphate-buffered saline. Endogenous
peroxidase activity was quenched with 0.6% hydrogen
peroxide in methanol for 15 min. Sections were blocked in
serum for 25 min, then incubated with the anti-Ab antibody
R1282 (1:1,000 dilution) [39], anti-NEP antibody 56C6 (1:100),
anti-GFP antibody A11122 (1:100), or anti-glial ﬁbrillary
acidic protein (GFAP) antibody (1:1,000; Dako, http://www.
dako.com/) for 2 h. After washing, an anti-rabbit or anti-
mouse biotinylated secondary antibody was applied for 30
min, washed, and developed using the avidin/biotin/HRP
method (ABC Elite Kit, Vector Labs) and DAB chromogenic
reaction (Liquid DAB, BioGenex, http://www.biogenex.com/).
Images were captured and quantiﬁed from approximately 20
stained sections per brain of each mouse using a 23 or 53
objective. Thioﬂavin-S staining was performed by incubating
tissue sections for 8 min in 1% thioﬂavin-S, followed by
washing in 80% and 95% ethanol, then water. The brain area
covered by Ab, thioﬂavin plaques, and GFAP staining was
determined in a blinded fashion using IPLab Spectrum 3.1
Image Analyzer software (Signal Analytics, http://www.
scanalytics.com/) and NIH ImageJ software [43]. The ratio
between the immunohistochemical and thioﬂavin staining on
the ipsilateral versus contralateral hemispheres was calcu-
lated for comparisons.
Statistical Analysis
The data were analyzed using a one-way analysis of
variance and Tukey post-hoc comparison or a two-tailed
Student t-test, where appropriate. Calculated comparisons of
p , 0.05 were considered signiﬁcant. All reported values
represent the means 6 standard error of the mean (SEM).
Results
NEP Expression and Generation of sNEP
Several studies point to NEP as one of the prominent Ab-
degrading proteases within the brain [9,15,44,45]. To deter-
mine the tissue distribution of NEP in the brain and several
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ebellum, and the basal ganglia/brainstem from the murine
brain and compared protein expression levels to those in the
liver, lung, and kidney. As positive and negative controls,
lysates from CHO cells transfected with NEP or empty vector
control were examined in parallel. Equal amounts of protein
from each sample were examined by quantitative ﬂuorescent
Western blotting. Because transfected NEP may run as a
Figure 1. Tissue Distribution of NEP and Generation of Secreted NEP
(A) Identical amounts of protein from transfected CHO cells and the indicated mouse tissues were probed by NEP immunoblot. CHO cells were transiently
transfectedwithemptyvector(CHO-control)orhumanNEP(CHO-NEP).Theindicatedperipheraltissuesandbrainregions(Bg/Bs,basalganglia/brainstem; Cb,
cerebellum;Ctx,cortex;Hip,hippocampus)werehomogenizedandprobedbyWesternblotforNEP.Thelowerblotisalongerexposureofthebrainsamples,
demonstrating low levels of NEP in the brain. Each sample was either left untreated ( ) or deglycosylated with PNGase F (þ) to remove N-linked sugars.
(B) Schematic representation of wild-type NEP and sNEP proteins. The sNEP construct was generated by replacing the NEP transmembrane (TM) domain
and cytosolic N terminus with a signal peptide (SP) ending at the luminal residue 52 of NEP. Cleavage of the signal peptide produces a soluble, secreted
form of NEP.
(C) NEP immunoblot of cellular lysates from CHO cells transfected with empty vector, NEP, or sNEP constructs.
(D) NEP activity assay in which the fluorogenic NEP substrate DAGNPG was incubated with lysates from CHO cells stably transfected with the indicated
constructs. NEP enzymatic activity was inhibited by phosphoramidon.
(E) NEP immunoblot of conditioned medium from CHO cells transfected with the indicated constructs.
(F) NEP activity assay on conditioned media from cells transfected with the indicated constructs. NEP activity assays of conditioned media (F) were
performed using the same relative amounts of material as for the lysates (D).
Immunoblots are representative of at least three experiments; NEP activity assays report the mean 6 SEM of six experiments.
doi:10.1371/journal.pmed.0040262.g001
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samples were assessed in the absence or presence of PNGase F
to remove N-linked glycosylation and reduce NEP immunor-
eactivity to a single signal. Mouse lung and kidney express
high levels of NEP that comigrates with transfected human
NEP, whereas the liver lacks NEP expression (Figure 1A). In
contrast to lung and kidney, brain levels of NEP are very low
and detectable only upon longer blot exposure (Figure 1A,
lower blot). Thus, although NEP has been characterized as an
essential protease for Ab catabolism, its protein expression
levels are relatively low in the brain compared to peripheral
tissues that express NEP. Moreover, since cerebral NEP
expression decreases with age and in AD [33,34], elevating
NEP levels could be neuroprotective by enhancing Ab
catabolism.
In exploring potential therapeutic approaches to reducing
brain Ab levels by elevating NEP expression, we evaluated a
secreted form of NEP, sNEP. A secreted Ab-degrading
protease would possess the advantage of diffusion through
the interstitial ﬂuid, where it may clear Ab at sites of
extracellular deposition. To generate this sNEP construct, we
used an overlapping PCR method to fuse the 29-amino acid
signal peptide from ACE to the luminal domain of NEP
beginning at residue 52 (Figure 1B). This construct, upon
being translated and inserted into the endoplasmic reticulum
membrane, has the signal peptide removed to liberate a
soluble, secreted form of NEP.
Transfecting cells with empty vector, NEP, or the sNEP
constructs and examining cell lysates by Western blotting
revealed a robust immunoreactive NEP band in the wild-type
NEP condition and a weaker, incompletely glycosylated, lower
molecular weight signal in the sNEP lane (Figure 1C).
Measuring NEP enzymatic activity in cell lysates demonstra-
ted NEP activity only in the wild-type NEP condition, and this
was inhibitable to baseline signal by the metalloprotease
inhibitor phosphoramidon (Figure 1D). The incompletely
glycosylated intracellular sNEP showed no enzymatic activity,
consistent with reports that glycosylation is required for NEP
activity [46]. Concentrating the conditioned media from these
cells for Western blot analysis revealed a strong signal for
sNEP, consistent with proper sNEP expression and secretion
(Figure 1E). Quantifying NEP activity in conditioned media
(using the same relative amount of material used for cell
lysates in Figure 1D) demonstrated robust NEP activity in the
sNEP samples alone, and this was again completely inhibited
by phosphoramidon (Figure 1F). These data demonstrate that
the sNEP construct is processed and secreted by cells as
expected and that sNEP is enzymatically active against a
prototypical NEP substrate.
sNEP Reduces Ab Levels in Cell Culture
To determine if the sNEP construct is able to degrade
naturally secreted Ab to a similar extent as wild-type NEP, we
cocultured CHO cells stably expressing APP at a 1:1 ratio with
CHO cells expressing either empty vector as control, wild-
type NEP, or sNEP. Cells were allowed to grow to conﬂuency,
and media were conditioned for Ab ELISA determinations.
Both wild-type NEP and sNEP were capable of promoting Ab
catabolism, with the NEP and sNEP conditions reducing Ab
levels in the media to 74% and 55% of control, respectively (p
, 0.01 for NEP and p , 0.001 for sNEP) (Figure 2A). These
reductions in Ab levels were not due to differences in the
proliferation rates of the cell lines, as there was equivalent APP
expression in each coculture condition (Figure 2B), indicating
a similar number of APP expressing cells at conﬂuency.
In order to clarify the location of NEP- and sNEP-mediated
Ab degradation, we mixed conditioned media from the APP-
overexpressing cell line with concentrated media from cells
Figure 2. Clearance of the Ab Peptide by NEP and sNEP
(A) CHO cells overexpressing APP were cocultured with CHO cells stably
expressing either empty vector, NEP, or sNEP constructs. Equal numbers
of cells were seeded, grown to confluence, and media were conditioned
for 18 h. Conditioned media were analyzed for total Ab levels by ELISA.
(B) Cellular lysates from the coculture in (A) were probed by Western
blotting for APP (which presents in both mature and immature
glycosylated forms), demonstrating equal amounts of APP expression.
Each condition is shown in duplicate.
(C) Conditioned media from CHO cells stably transfected with APP were
incubated in vitro with conditioned media from CHO cells expressing
empty vector, NEP, or sNEP. The conditioned media were combined and
incubated at 37 8C for 18 h. Ab levels were determined by ELISA.
The immunoblot for APP (B) is representative of four experiments; ELISA
values for Ab represent the mean 6 SEM of five experiments. For
comparisons to the empty vector condition, ** p , 0.01 and *** p , 0.001.
doi:10.1371/journal.pmed.0040262.g002
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sNEP-conditioned media exhibited an increased capacity to
degrade Ab compared to control (p , 0.001) (Figure 2C),
elevating the amount of Ab degraded 2-fold. Taken together,
these data demonstrate that wild-type NEP degrades Ab
principally while anchored to the cell membrane, whereas
sNEP is efﬁciently secreted into the extracellular environ-
ment to mediate Ab catabolism.
Generation of Viral and Cell-Based Ab-Degrading Vectors
To pursue an ex vivo gene delivery approach, we generated
lentiviral vectors able to efﬁciently transduce most cell types.
Retroviral vectors have been routinely utilized to genetically
enhance cells ex vivo prior to engraftment for the exper-
imental treatment of human diseases [47–49]. We inserted the
cDNA of sNEP or GFP (as control) into a lentiviral vector
driven by the cytomegalovirus promotor (Figure 3A). The
resulting vectors were able to transduce all cultured cell types
tested (HeLa, SH-SY5Y, SK-N-SH, HEK, CHO, and primary
and immortalized ﬁbroblasts), and produced high levels of
GFP or sNEP expression. To assess the ability of the sNEP
lentiviral vector to reduce Ab levels in APP overexpressing
cell lines, we transduced HEK cells stably expressing a familial
AD mutant form of APP695 and CHO cells stably expressing a
familial AD mutant form of APP751 with the sNEP or GFP
vectors. Examining cell lysates and conditioned media by
Western blot showed strong transgene expression, with HEK
cells attaining higher sNEP and GFP production than did
CHO cells (Figure 3B, top three blot pairs). Expression of
sNEP did not change APP levels in these cells compared with
GFP transduction (Figure 3B, fourth blot pair); however,
sNEP expression resulted in a marked decrease in Ab
monomer in the conditioned media (Figure 3B, ﬁfth blot
pair). Quantifying Ab levels in the conditioned media by
Figure 3. Characterization of a sNEP Lentiviral Construct
(A) Schematic representation of the lentiviral constructs expressing sNEP and GFP. Blocks indicate lentiviral genetic components. Internal promoters and
transgenes are indicated by arrows.
(B) HEK cells stably transfected with APP695 K595N/M596L (HEKAPP695) and CHO cells stably transfected with APP751 V717F (CHOAPP751) were
transduced with the lentiviral constructs in (A). Lysates and conditioned media (CM) were collected and probed for sNEP, GFP, APP, and Ab.
(C) Media from the lentivirally transduced cells were conditioned, and Ab levels were determined by ELISA.
Immunoblots are representative of four experiments; Ab ELISAs represent the mean 6 SEM of four experiments, compared to GFP transduced cells: ***
p , 0.001
doi:10.1371/journal.pmed.0040262.g003
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sNEP expression in both HEK and CHO APP-overexpressing
cell lines (p , 0.001) (Figure 3C).
Fibroblasts were chosen as the optimal cell type for use in ex
vivo gene delivery for a number of reasons. Fibroblasts survive
grafting into several organs, including the brain; they survive
and can sustain transgene expression for years [28]; they do
not form tumors or migrate from the graft site [47]; they cause
no detectible toxicity to the host tissue [50]; and they can be
noninvasively extracted from patients via skin biopsy. For this
study, ﬁbroblasts were prepared from the wild-type littermates
of the J20 APP transgenic mice. Cells were dissociated from
skin biopsies and plated in growth medium for brief
expansion in culture. Following their ﬁrst passage in culture,
the cells were transduced with either the sNEP or the GFP
lentiviral vector. The ﬁbroblasts transduced with GFP produce
a strong native ﬂuorescent signal (Figure 4A), while cells
transduced with sNEP robustly secrete the sNEP protein into
the extracellular medium (Figure 4B). To minimize the
possibility of in vitro cell transformation, the ﬁbroblasts used
in the study were not passaged more the ﬁve times before
engraftment into the experimental transgenic mice.
sNEP Cell Grafting Reduces Plaque Burden Locally and
Distal to the Implantation Site
A cohort of J20 APP transgenic mice was aged to achieve
signiﬁcant plaque deposition [42] for use in these studies. To
each of these mice, 500,000 cells expressing sNEP or GFP were
stereotaxically injected unilaterally into the hippocampus
(stereotaxic coordinates: AP  3.3 mm; L  3.3 mm; DV  3.12
and  1.9 mm), with the uninjected contralateral hippo-
campus serving as a control. Cells were injected at two
dorsoventral positions to better distribute the graft. The
brains of the mice were harvested and immunohistochemi-
cally assayed 28 d after surgery. Mice implanted with sNEP
grafts exhibited NEP immunoreactivity at the graft site, as
well as some diffuse NEP signal in nearby areas of the
hippocampus that extended approximately 800 lm from the
grafted cells (Figure 5A, right photomicrograph), consistent
with sNEP secretion. Endogenous NEP immunoreactivity is
localized to the cerebral blood vessels and the choroid plexus
(Figure 5A, left photomicrograph). GFP ﬁbroblasts exhibit
GFP staining restricted to the grafted cells (Figure 5B, right).
To determine the extent of Ab clearance from the brain
due to sNEP delivery, we stained sagittal sections for Ab
immunoreactivity from the medial to the lateral hippo-
campus. At the graft site, the ipsilateral hippocampus was
largely cleared of plaques near the sNEP-producing ﬁbro-
blasts (Figure 5E, right). There was some reduction in plaque
load at the GFP graft (Figure 5F, right), which was likely due
to the displacement of plaque-laden tissue by the grafted
GFP-expressing ﬁbroblasts. The ipsilateral hippocampus
medial to the graft site showed signiﬁcant reductions in Ab
immunoreactivity in the sNEP-injected mice (compared to
Figure 4. Generation of Primary Mouse Fibroblasts Expressing GFP and sNEP
Fibroblast cultures were generated from wild-type littermates of J20 APP transgenic mice.
(A) Live-cell fluorescent imaging of primary fibroblasts transduced with lentiviral vectors expressing GFP (top) or sNEP (bottom).
(B) Conditioned media from the primary fibroblasts were probed for the presence of sNEP. The immunoblot is representative of three experiments.
doi:10.1371/journal.pmed.0040262.g004
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Ab Clearance via Ex Vivo Gene DeliveryFigure 5. Reduction in Hippocampal Plaque Burden following sNEP Cell Engraftment
Aged J20 APP transgenic mice were implanted with fibroblasts expressing either sNEP (n¼5) (A, C, E, and G) or GFP (n¼3) (B, D, F, and H). Cells were
stereotaxically placed into the right (ipsilateral, right) hippocampus, with the uninjected left (contralateral, left) hippocampus serving as control. Brains
were harvested for analysis 28 d after surgery. Grafted cells were immunoreactive for either NEP (A) or GFP (B), with superior and inferior aspects of the
graft, respectively, indicated by arrows. Images (C–H) show staining for plaque burden at sites medial to the graft (C and D), at the site of the graft (E
and F), and at sites lateral to the graft (G and H). These fields were quantified by calculating the ratio of the area covered by plaques on the ipsilateral
versus the contralateral side; quantification was done in a blinded fashion. This ratio was determined separately for the sNEP and GFP groups and
compared at the hippocampus medial to the graft (I), the graft site (J), and the hippocampus lateral to the graft (K). Data represent the ratio’s mean 6
SEM, compared to GFP control: ** p ¼ 0.0020 for the medial hippocampus (I); * p ¼ 0.0269 for the graft site (J); and ** p ¼ 0.0081 for the lateral
hippocampus (K).
doi:10.1371/journal.pmed.0040262.g005
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Ab Clearance via Ex Vivo Gene Deliverythe uninjected contralateral hippocampus), whereas no effect
was observed in the GFP-injected mice (Figure 5C versus 5D,
respectively). Similarly, in the lateral hippocampus distal to
the graft, we observed signiﬁcant reductions in plaque
burden due to sNEP expression (Figure 5G versus 5H).
Changes in plaque burden were measured in blinded fashion
with automated image analysis, and the data expressed as a
ratio of the area covered by Ab plaque on the grafted
ipsilateral side versus the control contralateral side. Compar-
ing the ipsilateral/contralateral ratios of the sNEP and GFP
groups, signiﬁcant reductions in plaque burden were ob-
served in the ipsilateral hippocampus from mice engrafted
with sNEP-secreting ﬁbroblasts medial to the graft site (34%
reduction, p , 0.01), within the graft site (72% reduction, p ,
0.05), and lateral to the graft site (55% reduction, p , 0.01)
(Figure 5I–5K). Thus, ex vivo gene delivery of a soluble,
secreted form of human NEP resulted in substantial and
signiﬁcant reductions in Ab plaque burden both in the
vicinity of the graft and adjacent to the graft site.
Reduction in Thioflavin-Positive Plaques, but Not
Astrocytosis, Following sNEP Cell Engraftment
To determine if the engrafted sNEP was able to clear
ﬁbrillar plaques, we examined the number of thioﬂavin-
positive plaques in the ipsilateral and contralateral hippo-
campus. Sagittal sections throughout the hippocampus were
stained with thioﬂavin-S, and the ratio between the number
of plaques on the ipsilateral versus contralateral hippo-
campus was determined. Comparing the ipsilateral/contrala-
teral ratios from the sNEP and GFP groups, thioﬂavin-
positive plaques were reduced in the medial hippocampus
(40% reduction in plaque number, p , 0.05; Figure 6A and
6B) and at the graft site (51% reduction in plaque number, p
, 0.05; Figure 6C and 6D), but was not signiﬁcantly changed
in the lateral hippocampus of the sNEP engrafted brains
Figure 6. Reduction in Hippocampal Thioflavin Staining Following sNEP Cell Engraftment
Brain sections from mice engrafted with cells expressing sNEP or GFP were stained with thioflavin-S to quantify fibrillar plaques. Photomicrographs (A–
D) show thioflavin staining at sites medial to the graft (A and B) and at the site of the graft (C and D). Thioflavin-positive plaques were counted, and the
ratios of plaques on the ipsilateral versus contralateral hemispheres were calculated for sNEP and GFP groups for the medial hippocampus (E), the graft
site (F), and the lateral hippocampus (G). Data represent the mean 6 SEM, compared to GFP control: *p¼0.0432 for the medial hippocampus (E), and *p
¼ 0.0337 for the graft site (F). The difference at the lateral hippocampus was not significant.
doi:10.1371/journal.pmed.0040262.g006
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Ab Clearance via Ex Vivo Gene Deliverycompared to control (Figure 6E–6G). The lateral hippo-
campus had few or no thioﬂavin-positive plaques in either
condition and was thus not a reliable reporter of plaque
clearance. These data demonstrate that sNEP delivery
promotes the clearance of ﬁbrillar, thioﬂavin-positive pla-
ques from the brain of APP transgenic mice.
The activation of astrocyte growth (astrocytosis) is a marker
for brain inﬂammation, and astrocyte hypertrophy and
number are increased in AD and may play a role in disease
pathogenesis [1]. Transgenic expression of neprilysin has
been shown previously to reduce astrocytosis over the
lifetime of an APP-transgenic mouse [15], presumably due
to reductions in Ab accumulation. However, because we used
a surgical approach to exogenously deliver a soluble form of
NEP that clears existing plaques, there could be an
inﬂammatory response associated with plaque removal or
with the soluble protease itself. To examine this possibility,
we stained sNEP and GFP brains for the astrocyte GFAP. At
the site of cell engraftment, few astrocytes were found to have
inﬁltrated the graft, although there was a modest increase in
GFAP staining along the edge of the graft and along the
needle track (Figure 7A and 7B). However, comparing overall
hippocampal GFAP staining on the ipsilateral versus con-
tralateral hemispheres showed that there was no change in
astrocytosis due to cell engraftment or sNEP expression in
any region of the hippocampus (Figure 7C–7E). Thus, sNEP
cell delivery did not promote astrocytosis when measured at
28 d postimplantation. Future experiments examining longer
time points of sNEP delivery could show that brain
inﬂammation decreases after Ab clearance.
Discussion
Various approaches to lowering Ab levels within the brain
have come to represent the central focus in AD therapeutic
development. In this study, we describe the use of ex vivo
gene therapy as a viable approach to reducing Ab levels
utilizing a modiﬁed Ab-degrading protease. Replacing the
transmembrane domain of the normally membrane-anchored
NEP with a signal peptide resulted in the robust secretion of
an enzymatically active protease. When syngenic ﬁbroblasts
modiﬁed to produce sNEP were engrafted into aged APP
transgenic mice, the majority of the plaque burden surround-
ing the graft site was proteolytically cleared. Distal to the
graft, in both the medial and lateral hippocampus, signiﬁcant
reductions in plaque burden were also observed as a result of
sNEP gene delivery. These results demonstrate the utility of
locally elevating the expression of a secreted Ab-degrading
protease as a potential therapeutic approach for AD.
The ﬁnding that sNEP was able to reduce plaque burden
distal to the graft site may be explained by the diffusion of the
sNEP enzyme through the parenchyma, by diffusion of
soluble forms of Ab toward the graft (which may thus be
serving as an Ab sink), or both of these mechanisms. Because
Figure 7. No Change in Overall Astrocytosis following Cell Implantation
Brain sections from engrafted mice were stained for GFAP to probe for changes in astrocytosis.
(A and B) Compared to the contralateral hemisphere (A), the graft site (B) demonstrated an absence of GFAP staining within the graft and modestly
increased astrocyte staining along the border of the graft. The needle track is indicated by arrows and the graft by an asterisk. This staining pattern was
observed for both sNEP and GFP conditions (only sNEP is shown).
(C–E) The area staining for GFAP on the ipsilateral versus contralateral hippocampus was determined for the medial hippocampus (C), the graft site (D),
and the lateral hippocampus (E). Data represent the mean 6 SEM.
doi:10.1371/journal.pmed.0040262.g007
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were unable to detect sNEP diffusion farther than ;800 lm
from the graft site, nor could we detect the very low (Figure
1A) endogenous NEP levels expressed by neural tissue [51].
Potential side effects of sNEP expression may arise from
the degradation of NEP substrates other than Ab present in
the brain, such as enkephalins. Though studies explicitly
searching for such side effects were not performed here, no
adverse phenotype was reported in NEP transgenic mice that
were protected from Ab-induced premature death [15], and
in this study we observed no enhanced astrocytosis in
response to sNEP expression.
A major obstacle to translating the ex vivo methods used in
this study into a human disease therapy is the larger
dimensions of the human brain, which might require an
elevation in Ab-degrading activity throughout a much broad-
er area. However, our experiment involved just a 28 d
exposure to the sNEP-secreting cells, and we found these
primary cells to maintain transgene expression in vitro for
over a year. One approach to the problem of optimal
diffusion of the gene product is to implant the cells where
they may have the best access to circulating Ab, such as in the
cerebrospinal ﬂuid or the ventricular wall. Several studies
have reported the successful use of encapsulated cell implants
that allow for diffusion of therapeutic factors into biological
ﬂuids, including cerebrospinal ﬂuid [29,30]. By analogy to the
peripheral sink hypothesis for Ab immunotherapy [52], it may
also be feasible and attractive to implant genetically modiﬁed
cells into peripheral compartments (e.g., the peritoneal cavity
or skeletal muscle), where they may substantially increase the
Ab-degrading capacity of the periphery and thus increase the
rate of efﬂux of Ab across the blood–brain barrier. Moreover,
some of the secreted sNEP provided by such a peripheral
implant may reach the brain and cerebrospinal ﬂuid to help
decrease brain Ab levels directly. The existence of a subset of
hematopoietic cells capable of inﬁltrating the brain and
surrounding plaques has been described [53,54]. Though these
cells may not efﬁciently degrade Ab themselves, if they could
be modiﬁed to express an Ab-degrading protease in a manner
similar to the approach we report here, they may provide an
anatomically targeted means for local Ab elimination.
In summary, our ﬁndings demonstrate that ex vivo gene
delivery of an Ab-degrading protease rapidly lowers hippo-
campal Ab plaque burden in a mouse model of Alzheimer
disease. Ex vivo gene delivery and other strategies to elevate
Ab-degrading activity in Alzheimer patients warrant further
investigation as potential therapeutic approaches to treat this
common and devastating disease.
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Editors’ Summary
Background. Alzheimer disease is the most common form of dementia
and is increasingly common as people age. It may affect up to half of the
population in people over 85 years of age. The classic pathological
features of Alzheimer disease in the brain were described 100 years ago
by a German neuropathologist, Alois Alzheimer. They consist of plaques,
which are made up of a protein called amyloid-b protein (shortened to
Ab); and tangles of another protein, called tau. These proteins
accumulate especially in areas of the brain where memory and thought
are processed and are believed to be toxic to neurons. There are a
number of inherited forms of Alzheimer disease which are caused by
mutations either in the protein from which Ab is derived, called beta-
amyloid precursor protein (shortened to APP) or in other proteins that
act to release the Ab protein from APP. Research on these inherited
forms of Alzheimer disease has helped in the understanding of how
plaques accumulate, which has subsequently led to new potential
approaches to the treatment of Alzheimer disease such as lowering the
production of Ab from APP or enhancing clearance of the plaques.
Why Was This Study Done? The researchers here wanted to investigate
the use of a type of gene therapy called ex vivo (which means out of
body) gene therapy, in which cells are taken from an individual,
genetically altered, then put back into the individual they were taken
from. This approach has already been studied in some human diseases
and conditions including hemophilia, cancer, and spinal cord injury. The
researchers here wanted to investigate whether they could use this
approach to deliver to the brain one of the proteases that breaks down
amyloid plaques.
What Did the Researchers Do and Find? The researchers used a mouse
model of Alzheimer disease in which, as the mice age, they develop
plaques in the brain made of the same protein found in human
Alzheimer disease. The researchers took a particular type of cell from the
mice called a fibroblast, used a virus called a lentivirus to insert into the
cells a protease called neprilysin that can degrade Ab, and then injected
these altered cells into the brains of the mice. They then compared
results of these experiments with what happened when cells with a
control (an inactive virus) were injected. They found that when the active
protease was put into the brains of mice there was a substantial clearing
of plaques especially in the areas close to the injection site, compared
with the control mice.
What Do These Findings Mean? These results suggest that this ex vivo
gene therapy approach to Alzheimer disease is worth considering
further. However, despite showing that the plaques were cleared the
researchers did not show whether or not there was any effect on the
behavior of the mice, i.e., whether there was any effect on the symptoms
that the plaques cause. In addition, before this approach could be used
in humans more work would need to be done, including showing that
the lentivirus and the protease used were safe in humans, and the
injection could be scaled up to the much larger human brain.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040262.
  The slides from the original cases that Alois Alzheimer described are
available online
  Current research is discussed by the Alzheimer Research Forum
  News and information for researchers, doctors, and patients, including
a 24-hour help line, are available from the Alzheimer’s Association
  Medline Plus, the health information site for patients from the US
National Library of Medicine, has a page of links on Alzheimer disease
  The US National Institutes of Health National Institute of Aging has a
fact sheet on Alzheimer disease, which is also available in Spanish
  The UK’s National Health Service online information site has
information on Alzheimer disease
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